Fosravuconazole
- D01BA03 (WHO)
- In general: ℞ (Prescription only)
- [(2R,3R)-3-[4-(4-Cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate
- 351227-64-0
- 9807507
- L4Q6O5430L
- D10762
- DTXSID70188627
- Interactive image
- C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F
- InChI=1S/C23H20F2N5O5PS/c1-15(22-29-21(10-37-22)17-4-2-16(9-26)3-5-17)23(11-30-13-27-12-28-30,34-14-35-36(31,32)33)19-7-6-18(24)8-20(19)25/h2-8,10,12-13,15H,11,14H2,1H3,(H2,31,32,33)/t15-,23+/m0/s1
- Key:SYTNEMZCCLUTNX-NPMXOYFQSA-N
Fosravuconazole (trade name Nailin) is a triazole antifungal agent.[1][2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail.[3] It is a prodrug that is converted into ravuconazole.[1]
Drugs for Neglected Diseases Initiative (DNDi) and the Japanese pharmaceutical company Eisai found that fosravuconazole works as a treatment for mycetoma, a serious condition.[1][4][5] The Phase II clinical trial found that oral fosravuconazole was safe, patient-friendly, and effective in treating eumycetoma.[6][7] Eumycetoma mainly affects young adults in poorer, rural areas; the standard treatment is itraconazole, which is much more expensive at about US$2,000 for a year than fosravuconazole and unaffordable, and not available in all endemic countries.[7]
References
- ^ a b c Yamaguchi H (2016). "Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis". Medical Mycology Journal. 57 (4): E93–E110. doi:10.3314/mmj.16-00006. PMID 27904057.
- ^ "Fosravuconazole - Seren Pharmaceuticals". Adis Insight. Springer Nature Switzerland AG.
- ^ "Oral Antifungal Agent Nailin Capsules 100 mg Approved in Japan" (Press release). Eisai. January 19, 2018.
- ^ "Fosravuconazole". Drugs for Neglected Diseases Initiative. 23 November 2023 [Project started in 2015; updated in 2023 with results of the Phase II clinical trial].
- ^ "Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma" (Press release). Eisai Co., Ltd. 10 September 2015.
- ^ "World's first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment" (Press release). Drugs for Neglected Diseases initiative (DNDi). 23 November 2023.
- ^ a b Johnson, Sarah (23 November 2023). "Cheap over-the-counter nail drug found to work on crippling flesh-eating disease". The Guardian.
The head of mycetoma at the DNDi labelled the discovery 'momentous', and said 'We were all very excited, it's going to be a gamechanger'.
- v
- t
- e
membrane
Ergosterol inhibitors |
| ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
β-glucan synthase inhibitors |
Pyrimidine analogues/ thymidylate synthase inhibitors |
|
---|---|
Mitotic inhibitors |
|
Aminoacyl tRNA synthetase inhibitors |
|
- bromochlorosalicylanilide
- chlorophetanol
- chlorphenesin
- ciclopirox
- crystal violet
- dimazole
- ethylparaben
- haloprogin‡
- polynoxylin
- potassium iodide#
- salicylic acid
- selenium disulfide#
- sodium thiosulfate#
- sulbentine
- taurolidine
- ticlatone
- tolciclate
- tolnaftate
- tribromometacresol
- undecylenic acid
- Whitfield's ointment#
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III